GCTK
HEALTHCAREGlucoTrack Inc
AI Insight
What's Moving GCTK Today?
No stock-specific AI insight has been generated for GCTK yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.29$15.90
$0.36
Fundamentals
Market Cap$2M
P/E Ratio0.1
EPS$6.06
Dividend Yield—
Dividend / Share—
ROE-527.0%
Profit Margin—
Debt / Equity—
Trading
Volume216K
Avg Volume (10D)—
Shares Outstanding6.3M
GCTK News
22 articles- Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific SessionsYahoo Finance·May 26, 2026
- Glucotrack Received Notice of DelistingTradingView·May 16, 2026
- Armistice Capital (GCTK) reports 102,115 shares, 4.99% ownershipStock Titan·May 15, 2026
- Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsYahoo Finance·May 14, 2026
- Glucotrack Submits Blood Glucose Monitoring Technology to FDAYahoo Finance·May 7, 2026
- Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring TechnologyYahoo Finance·May 7, 2026
- Glucotrack Shows Long-Term Accuracy of Implantable Glucose MonitorYahoo Finance·Apr 30, 2026
- Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring TechnologyYahoo Finance·Apr 30, 2026
- Study Supports GlucoTrack’s Blood Glucose Monitoring ImplantYahoo Finance·Apr 21, 2026
- Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring TechnologyYahoo Finance·Apr 21, 2026
- Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate HighlightsGlobeNewswire Inc.·Mar 30, 2026
- Glucotrack to File for FDA Exemption Based on 2025 MilestonesYahoo Finance·Mar 28, 2026
- BC-Most Active StocksYahoo Finance·Mar 27, 2026
- Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 MilestonesYahoo Finance·Mar 27, 2026
- Glucotrack to Present at LSI USA ’26 Medtech Innovation SummitYahoo Finance·Mar 10, 2026
- Glucotrack Announces 3 New Patents to Monitor Blood GlucoseYahoo Finance·Jan 29, 2026
- Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM PlatformYahoo Finance·Jan 29, 2026
- Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional InvestorYahoo Finance·Dec 30, 2025
- Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate HighlightsYahoo Finance·Nov 13, 2025
- Glucotrack, Inc. Encourages Shareholders to VoteYahoo Finance·Nov 3, 2025
- Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory TeamYahoo Finance·Oct 29, 2025
- Glucotrack, Inc. Reminds Shareholders to VoteYahoo Finance·Oct 28, 2025
All 22 articles loaded
Price Data
Open$0.36
Previous Close$0.36
Day High$0.37
Day Low$0.35
52 Week High$15.90
52 Week Low$0.29
52-Week Range
$0.29$15.90
$0.36
Fundamentals
Market Cap$2M
P/E Ratio0.1
EPS$6.06
Dividend Yield—
Dividend / Share—
ROE-527.0%
Profit Margin—
Debt / Equity—
Trading
Volume216K
Avg Volume (10D)—
Shares Outstanding6.3M
About GlucoTrack Inc
GlucoTrack, Inc., a medical device company, designs, develops and markets noninvasive glucose monitoring devices for people with diabetes and prediabetes in Europe and Asia Pacific. The company is headquartered in Or Yehuda, Israel.
HEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICMEDICAL INSTRUMENTS & SUPPLIES
CIK—
Composite FIGI—
Share Class FIGI—